SEC okays Covaxin phase-3 trials data, 77.8% efficacy

A day ahead of Bharat Biotech’s pre-submission meeting with the World Health Organisation (WHO) for emergency use listing (EUL) for Covaxin, the subject expert committee (SEC) has given its nod to the vaccine’s phase-3 efficacy trials data.

Admin Admin
Jun 23, 2021 - 09:30
0 6
SEC okays Covaxin phase-3 trials data, 77.8% efficacy
Linkup
A day ahead of Bharat Biotech’s pre-submission meeting with the World Health Organisation (WHO) for emergency use listing (EUL) for Covaxin, the subject expert committee (SEC) has given its nod to the vaccine’s phase-3 efficacy trials data.
Read More